Roivant, Ve­ra seek $100M+ rais­es as they look to fund drug hope­fuls

Two life sci­ences com­pa­nies — Roivant Sci­ences and Ve­ra Ther­a­peu­tics — are plan­ning to bring in at least $100 mil­lion in new cash soon.

Roivant an­nounced Wednes­day af­ter­noon it’s set­ting up a pub­lic of­fer­ing with the goal of rais­ing $150 mil­lion, while Ve­ra priced a stock of­fer­ing at $7 per share, ex­pect­ing to reel in $100 mil­lion. The moves come as the two are chart­ing cours­es for the months ahead: Roivant with a new drug from Pfiz­er and Ve­ra with an up­com­ing Phase III study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER